|1.||Herold, Betsy C: 6 articles (01/2011 - 06/2004)|
|2.||Cheshenko, Natalia: 5 articles (01/2011 - 06/2004)|
|3.||Keller, Marla J: 5 articles (08/2009 - 06/2004)|
|4.||Profy, Albert: 4 articles (04/2011 - 05/2008)|
|5.||Wilson, Sarah S: 4 articles (01/2011 - 05/2007)|
|6.||Shattock, Robin J: 4 articles (01/2011 - 01/2006)|
|7.||Klotman, Mary E: 4 articles (01/2011 - 06/2004)|
|8.||Mesquita, Pedro M M: 4 articles (01/2011 - 01/2006)|
|9.||Ramjee, Gita: 3 articles (08/2014 - 10/2010)|
|10.||Fakioglu, Esra: 3 articles (01/2011 - 01/2009)|
01/01/2006 - "PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial."
10/16/2010 - "We randomly assigned sexually active women, aged 18 years or older (≥16 years in Tanzania and Uganda) without HIV-1 infection in a 1:1:1 ratio to 2% PRO2000, 0·5% PRO2000, or placebo gel groups for 52 weeks (up to 104 weeks in Uganda). "
05/01/2008 - "While efficient blocking of MDDC-mediated virus transfer and infection in the highly permissive MDDC-T-cell environment reinforces the potential value of PRO 2000 as a topical microbicide against HIV, the impact of PRO 2000 on immune cell functions warrants careful evaluation."
01/01/2006 - "Our results demonstrate that PRO 2000 is a potent inhibitor of R5 HIV-1 infection and dissemination pathways in human cervical explants. "
01/01/2006 - "PRO 2000 efficiently inhibited infection of cervical explants and dissemination of virus by migratory DC. "
|2.||Sexually Transmitted Diseases (Sexually Transmitted Disease)
07/01/2009 - "These include the Mwanza study of syndromic management of sexually transmitted diseases and three male circumcision trials in East Africa; a microbicide trial reported in 2009 shows substantial promise for the efficacy of PRO 2000 (0.5% gel). "
07/01/1999 - "Vaginal gel formulations containing the naphthalene sulfonate polymer PRO 2000 are being developed as topical microbicides to protect against infection with sexually transmitted disease (STD) pathogens. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||HIV Infections (HIV Infection)
05/01/2008 - "The sulfonated polyanion PRO 2000, a candidate topical microbicide now in phase II/III clinical trials, blocks HIV infection of cervical tissue in vitro. "
05/01/2008 - "Continuous exposure to PRO 2000 during MDDC-target cell coculture effectively inhibited HIV infection of target cells. "
02/01/2008 - "Indevus Pharmaceuticals Inc, under license from Paligent Inc, is developing PRO-2000, an antimicrobial gel for the prevention of HIV infection. "
02/01/2008 - "PRO-2000, an antimicrobial gel for the potential prevention of HIV infection."
08/01/2012 - "Topical products that were ineffective in preventing HIV infection include BufferGel, Carraguard, and PRO 2000. "
06/19/2009 - "Among the products assessed in more than one study, there were significantly more genital findings with intact epithelium in recipients of PRO2000 [relative risk (RR) 1.68, 95% confidence interval (CI) 1.08-2.60] and a lower incidence of bacterial vaginosis in dextrin sulphate recipients (RR 0.61, 95% CI 0.42-0.88). "
|5.||Vaginal Creams, Foams, and Jellies (Vaginal Tablet)
|7.||antineoplaston A10 (A 10)
|9.||cellulose acetate phthalate
|10.||Anti-Infective Agents (Microbicides)
|1.||Male Circumcision (Circumcision)